© The Author 2006. Published by Oxford University Press.
ARTICLE |
Bacteria-Eradicating Therapy With Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial
Affiliations of authors: Units of Medical Oncology (AJMF, GPD), Pathology (MP, CD), Ophthalmology (AGR), and Neuroradiology (LSP), San Raffaele H Scientific Institute, Milan, Italy; Immunovirology and Biotherapy Unit, Department of Pre-Clinical and Epidemiological Research, Centro di Riferimento Oncologico, Instituto di Ricerca e Cura a Carattere Scientifico (IRCCS), National Cancer Institute, Aviano, Italy (MG, EP, AAL, FS, RD); Divisione di Ematologia, Ospedale Riuniti di Bergamo, Bergamo, Italy (SC); First Department of Medicine, Semmelweis University, Budapest, Hungary (JD); Hematology and Bone Marrow Transplantation Unit, Istituto Nazionale dei Tumori, Milan, Italy (FZ); Division of Hematology, Ospedale San Francesco, Nuoro, Italy (AP); Division of Hematology, IRCCS Niguarda Cà Granda, Milan, Italy (GM); Ophthalmology Unit, Ospedale San Giuseppe, Milan, Italy (CDC)
Correspondence to: Andrés J. M. Ferreri, MD, Medical Oncology Unit, Department of Oncology, San Raffaele H Scientific Institute, Via Olgettina 60, 20132 Milan, Italy (e-mail: andres.ferreri{at}hsr.it).
Background: An association between ocular adnexal MALT lymphoma (OAL) and Chlamydia psittaci (Cp) infection has been proposed, and recent reports suggest that doxycycline treatment causes tumor regression in patients with Cp-related OAL. The effectiveness of doxycycline treatment in Cp-negative OAL has not been tested. Methods: In a prospective trial, 27 OAL patients (15 newly diagnosed and 12 having experienced relapse) were given a 3-week course of doxycycline therapy. Objective lymphoma response was assessed by computerized tomography scans or magnetic resonance imaging at 1, 3, and 6 months after the conclusion of therapy and every 6 months during follow-up. Cp infection in patients was determined by touchdown enzyme time-release polymerase chain reaction (TETR-PCR). Statistical tests were two-sided. Results: Eleven patients were Cp DNA–positive and 16 were Cp DNA negative. Doxycycline was well tolerated. At a median follow-up of 14 months, lymphoma regression was complete in six patients, and a partial response (
50% reduction of all measurable lesions) was observed in seven patients (overall response rate [complete and partial responses] = 48%). Lymphoma regression was observed in both Cp DNA–positive patients (seven of 11 experienced regression) and Cp DNA–negative patients (six of 16 experienced regression) (64% versus 38%; P = .25, Fisher's exact test). The three patients with regional lymphadenopathies and three of the five patients with bilateral disease achieved objective response. In relapsed patients, response was observed both in previously irradiated and nonirradiated patients. The 2-year failure-free survival rate among the doxycycline-treated patients was 66% (95% confidence interval = 54 to 78), and 20 of the 27 patients were progression free. Conclusions: Doxycycline is a fast, safe, and active therapy for Cp DNA–positive OAL that was effective even in patients with multiple failures involving previously irradiated areas or regional lymphadenopathies. The responses observed in PCR-negative OAL may suggest a need for development of more sensitive methods for Cp detection and investigation of the potential role of other doxycycline-sensitive bacteria.
CiteULike 
Connotea 
Del.icio.us What's this?
Find additional patient-related information at:
Editorial about this Article
- Chlamydia or Not Chlamydia, That Is the Question: Which Is the Microorganism Associated With MALT Lymphomas of the Ocular Adnexa?
- Emanuele Zucca and Francesco Bertoni
J Natl Cancer Inst 2006 98: 1348-1349.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy Ann. Onc., May 1, 2008; 19(5): 835 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M L Cohen, J. Sweetenham, and A. D Singh Ocular adnexal lymphoma. What is the evidence for an infectious aetiology? Br. J. Ophthalmol., April 1, 2008; 92(4): 446 - 448. [Full Text] [PDF]
|
|
|
|
|
|
E.-K. Song, S.-Y. Kim, T. M. Kim, K.-W. Lee, T. Yun, I.-I. Na, H. Shin, S. H. Lee, D. W. Kim, S. I. Khwarg, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma Ann. Onc., February 1, 2008; 19(2): 242 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. M. Ferreri, G. P. Dognini, M. Ponzoni, L. Pecciarini, M. G. Cangi, G. Santambrogio, A. G. Resti, C. De Conciliis, S. Magnino, E. Pasini, et al. Chlamydia psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma Ann. Onc., January 1, 2008; 19(1): 194 - 195. [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. M. Ferreri, R. Dolcetti, S. Magnino, C. Doglioni, M. G. Cangi, L. Pecciarini, P. Ghia, A. Dagklis, E. Pasini, N. Vicari, et al. A Woman and Her Canary: A Tale of Chlamydiae and Lymphomas J Natl Cancer Inst, September 19, 2007; 99(18): 1418 - 1419. [Full Text] [PDF]
|
|
|
|
|
|
A. Ferreri, R Dolcetti, P Musto, G. Dognini, C Doglioni, and M Ponzoni Reply to the article 'Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)' by P. Arnaud, M.-C. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369) Ann. Onc., February 1, 2007; 18(2): 401 - 403. [Full Text] [PDF]
|
|
|
|
|
|
E. Zucca and F. Bertoni Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa? J Natl Cancer Inst, October 4, 2006; 98(19): 1348 - 1349. [Full Text] [PDF]
|
|